Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials

被引：0
|
作者：
Neyns, Bart
Weber, Jeffrey S.
Lebbe, Celeste
Maio, Michele
Harmankaya, Kaan
Hamid, Omid
O'Day, Steven
Chin, Kevin M.
McDowell, Diane Opatt
Cykowski, Lori
McHenry, Brent
Wolchok, Jedd D.
机构：
[1] UZ Brussel, Brussels, Belgium
[2] Comprehens Melanoma Res Ctr, H Lee Moffitt Canc Ctr, Tampa, FL USA
[3] Hop St Louis, Paris, France
[4] Ist Toscano Tumori, Univ Hosp Siena, Siena, Italy
[5] Med Univ Vienna, Div Gen Dermatol, Dept Dermatol, Vienna, Austria
[6] Angeles Clin & Res Inst, Los Angeles, CA USA
[7] Beverly Hills Canc Ctr, Beverly Hills, CA USA
[8] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[9] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[10] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9059
引用
收藏
页数：1
相关论文
共 50 条
  • [41] MODELLING THE COST-EFFECTIVENESS OF IPILIMUMAB FOR PREVIOUSLY-TREATED, METASTATIC MELANOMA
    Lee, D.
    Winn, B.
    Lebmeier, M.
    Batty, A.
    VALUE IN HEALTH, 2012, 15 (07) : A423 - A423
  • [42] Efficacy of ipilimumab 3mg/kg following progression on low dose ipilimumab in metastatic melanoma.
    Lai-Kwon, Julia Elizabeth
    Jacques, Sarah
    Carlino, Matteo S.
    Benannoune, Naima
    Robert, Caroline
    Allayous, Clara
    Baroudjian, Barouyr
    Lebbe, Celeste
    Zimmer, Lisa
    Eroglu, Zeynep
    Topcu, Turkan Ozturk
    Dimitriou, Florentia
    Haydon, Andrew Mark
    Lo, Serigne N.
    Menzies, Alexander M.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Overall survival at 5 years of follow-up from a phase 3 trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
    Ascierto, Paolo A.
    Del Vecchio, Michele
    Mackiewicz, Andrzej
    Robert, Caroline
    Chiarion-Sileni, Vanna
    Arance, Ana
    Lebbe, Celeste
    Svane, Inge Marie
    McNeil, Catriona
    Rutkowski, Piotr
    Loquai, Carmen
    Mortier, Laurent
    Hamid, Omid
    Bastholt, Lars
    Dreno, Brigitte
    Schadendorf, Dirk
    Garbe, Claus
    Nyakas, Marta
    Grob, Jean-Jacques
    Thomas, Luc
    Liszkay, Gabriella
    Smylie, Michael
    Burcin, Simsek
    Hosein, Fareeda
    Maio, Michele
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17
  • [44] Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
    Weber, Jeffrey
    Gibney, Geoffrey
    Kudchadkar, Ragini
    Yu, Bin
    Cheng, Pingyan
    Martinez, Alberto J.
    Kroeger, Jodie
    Richards, Allison
    McCormick, Lori
    Moberg, Valerie
    Cronin, Heather
    Zhao, Xiuhua
    Schell, Michael
    Chen, Yian Ann
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (04) : 345 - 353
  • [45] A phase 1 study of NY-ESO-1 vaccine + ipilimumab (ipi) in patients with unresectable or metastatic melanoma
    Slingluff, Craig
    Zarour, Hassane
    Postow, Michael
    Friedlander, Philip
    Devoe, Craig
    Mauldin, Ileana
    Smith, Kelly
    Macri, Mary
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [46] Phase II study of perifosine in previously untreated patients with metastatic melanoma
    Ernst, DS
    Eisenhauer, E
    Wainman, N
    Davis, M
    Lohmann, R
    Baetz, T
    Belanger, K
    Smylie, M
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (06) : 569 - 575
  • [47] Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma
    D Scott Ernst
    Elizabeth Eisenhauer
    Nancy Wainman
    Mary Davis
    Reinhard Lohmann
    Tara Baetz
    Karl Belanger
    Michael Smylie
    Investigational New Drugs, 2005, 23 : 569 - 575
  • [48] Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL).
    Weber, Jeffrey S.
    Larkin, James M. G.
    Schadendorf, Dirk
    Wolchok, Jedd D.
    Wagstaff, John
    Dummer, Reinhard
    Hogg, David
    Guidoboni, Massimo
    Sosman, Jeffrey Alan
    Chmielowski, Bartosz
    Gerritsen, Winald
    Bhore, Rafia
    Walker, Dana
    Gonzalez, Rene
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
    Chapman, Paul B.
    Jayaprakasam, Vetri Sudar
    Panageas, Katherine S.
    Callahan, Margaret
    Postow, Michael A.
    Shoushtari, Alexander N.
    Wolchok, Jedd D.
    Warner, Allison Betof
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
  • [50] Descriptive analysis of the use of ipilimumab (IPI) in previously treated patients with unresectable stage III or IV metastatic melanoma (MM) in four university hospitals of Quebec, Canada.
    Jolivet, Catherine
    Jamal, Rahima
    Belanger, Karl
    Marcotte, Nathalie
    Guevremont, Chantal
    Berard, Ghislain
    Michel, Marie-Claude
    Pelletier, Elaine
    Varin, France
    Deschenes, Louise
    Froment, Daniel
    Farand, Paul
    Rajan, Raghu
    LeTarte, Nathalie
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345